Your Complete Guide to Global Clinical Research and GCP Compliance
Understanding EU-CTR & EudraLex Vol 10: A Checklist to Keep Trial Search Clinical Studies Inspection-Ready Comprehensive Checklist for EU-CTR & EudraLex Vol 10 Compliance in Trial Search Clinical Studies In the complex landscape of global clinical trials, maintaining compliance with regulatory frameworks such as the EU Clinical Trials Regulation (EU-CTR) and EudraLex Volume 10 is…
Understanding EU-CTR & EudraLex Vol 10: How checkmate 649 trial Teams Maintain Inspection Readiness Comprehensive Guide to EU-CTR & EudraLex Vol 10: Ensuring Inspection Readiness in the checkmate 649 trial The regulatory landscape governing clinical trials is complex and evolving, particularly for multinational studies such as the checkmate 649 trial. This article provides a detailed…
Aligning Site and Sponsor Perspectives in IIT Clinical Trials: Operational and Oversight Best Practices Investigator initiated trials (IIT clinical trials) represent a unique and increasingly important segment of clinical research, where the principal investigator (PI) or site takes the lead in study conception and execution, often with varying degrees of sponsor involvement. For clinical operations,…
Sustainable & Green R&D Practices: ESG Strategy, Green Chemistry, and Compliance-Ready Playbooks Greener R&D That Passes Inspection: How to Design Low-Impact Labs, Processes, and Supply Chains Why sustainability in R&D is now a compliance issue—and how to frame it for regulators, investors, and patients Sustainability in pharmaceutical R&D is no longer a “nice to have.”…
Hybrid Transition & Change Management in DCTs: A Compliance-First Playbook (2025) Managing Hybrid Transitions and Change With Regulatory Confidence Why Hybridization Now: Principles, Roles, and the Regulatory Frame Most sponsors do not leap from site-centric research to fully decentralized trials; the durable pattern is a hybrid operating model that blends on-site, in-home, and virtual procedures….
Read More “Hybrid Transition & Change Management in DCTs: A Compliance-First Playbook (2025)” »
Rare & Ultra-Rare Development Models: Small-Population Designs, Global Pathways, and Lifecycle Evidence Designing Rare and Ultra-Rare Trials That Win: From Small-n Statistics to Global Regulatory and Access Strategy Strategy for tiny populations: feasibility first, then a fit-for-purpose development model Rare and ultra-rare programs succeed when they start with ruthless feasibility and a development model that…
Data Integrity & Monitoring in DCTs: Making Every Number Click to Proof (2025) Engineering Data Integrity and Risk-Based Monitoring for Decentralized Trials Principles, Roles, and the Global Compliance Frame for DCT Data Integrity Decentralized and hybrid trials distribute evidence creation across homes, phones, couriers, and community clinics. That dispersion does not dilute obligations to protect…
Read More “Data Integrity & Monitoring in DCTs: Making Every Number Click to Proof (2025)” »
IP, Exclusivity & Lifecycle Strategies: From Patent Landscaping to PTE/SPC and Post-Approval Value Protection Building Defensible Exclusivity: Practical IP, Regulatory, and Lifecycle Playbooks for Modern R&D Set the foundation: strategy-first IP that de-risks science, unlocks markets, and travels globally Winning in pharmaceutical R&D requires more than a great molecule—it requires a durable moat. That moat…
Safety & Emergency Procedures at Home in DCTs: A Clinically Robust, Inspection-Ready Playbook (2025) Managing Safety and Emergencies at Home Without Compromising Rigor Safety by Design: Principles, Roles, and the Global Compliance Frame In decentralized and hybrid clinical trials (DCTs), the clinical environment follows the participant—into living rooms, workplaces, pharmacies, and community clinics. That shift…
Remote & Virtual Inspections: Governance, Security, and Evidence Flow for Global GCP Readiness Remote and Hybrid Inspections: Operational Playbook for Digital-First GCP Readiness Ground Rules & Governance: Making Remote Inspections Lawful, Ethical, and Effective Why remote? Remote and hybrid inspections compress travel time and broaden coverage, but they raise new questions about access, privacy, and…
Don’t leave empty-handed. Watch practical GMP scenarios, inspection lessons, deviations, CAPA thinking, and real compliance insights on our YouTube channel. One click now can save you hours later.